FDA grants priority review of Sanofi’s biologics license application for sutimlimab

The U.S. Food and Drug Administration (FDA) has granted priority review of Sanofi’s Biologics License Application (BLA) for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease (CAD). Sutimlimab, an investigational monoclonal antibody, targets the underlying cause of hemolysis in CAD by selectively inhibiting complement C1s.

source https://www.pharmatutor.org/pharma-news/2020/fda-grants-priority-review-of-sanofi-biologics-license-application-for-sutimlimab